Albiruni Razak

17PUBLICATIONS
196CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biologyLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 13, 2026
Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

|Jun 10, 2026
Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

|Jun 04, 2026
Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft-Tissue Sarcoma.

|Mar 13, 2026
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.

Albiruni Razak, Amit Mahipal, Jennifer R Diamond

|May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE.

Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom

|May 12, 2025
First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.

Benedito A Carneiro, Olumide B Gbolahan, Albiruni Abdul Abdul Razak

Pageof 3

Frequent Collaborators

6 joint publications

Philippe L Bedard

5 joint publications

Aaron R Hansen

4 joint publications

Anna Spreafico

4 joint publications

Jean-Yves Blay